Forbes -- He is supposed to be the best turnaround guy in the drug business. But right now Hassan looks like he made millions while his investors lost money. Hassan received $13 million in cash that would have been endangered had a high-profile study of the cholesterol drugs Vytorin and Zetia been released in November 2006 or March 2007 as cardiologists widely expected. The final release of the study this year has caused a sharp drop in the use of the two drugs and in Schering-Plough’s stock price. Read full article below.
